冠心病合并2型糖尿病患者血清MMP-9,TIMP-1及hs-CRP水平的检测及其临床意义

目的：探讨外周静脉血清基质金属蛋白酶-9（MMP-9）、基质金属蛋白酶组织抑制剂-1（TIMP-1）、高敏C反应蛋白（hs-CRP）水平与冠心病（CHD）合并2型糖尿病（T2DM）的关系并评价其临床意义。方法：选取CHD合并T2DM患者31例,单纯CHD患者50例,选择门诊体检者30例为正常对照组。用酶联免疫吸附法（ELISA）检测血清MMP-9,TIMP-1,用免疫散射比浊法检测血清hs-CRP的表达情况。结果：CHD合并T2DM组血清MMP-9的浓度（M=409.62ng/mL）显著高于CHD组（M=263.40ng/mL）及对照组（196.15±44.89）ng/mL（]均P＆lt;0.05）。CHD合并T2DM组血清TIMP-1的浓度（229.27±46.85）ng/mL]低于对照组（272.75±72.35）ng/mL（]P＆lt;0.05）。CHD合并T2DM组血清hs-CRP的浓度（M=17.20mg/L）明显高于CHD组（M=4.57mg/L）及对照组（1.52±0.78）mg/L（]均P＆lt;0.01）。CHD合并T2DM组患者血清MMP-9,TIMP-1与hs-CRP的浓度呈正相关。结论：联合检测...

Detection of MMP-9,TIMP-1 and hs-CRP in coronary heart disease patients with type 2 diabetes mellitus and the clinical significance

Objective： To explore the effect of matrix metalloproteinase-9 （MMP-9）,tissue inhibitor of metalloproteinase-1 （TIMP-1） and high sensitive C-reactive protein （hs-CRP） in coronary heart diseas（eCHD）with type 2 diabetes mellitus （T2DM）. Methods： Thirty one CHD with T2DM and 50 patiens with CHD were chosen;and 30 healthy volunteers served as control group. MMP-9 and TIMP- 1 in serum were measured with ELISA, hs-CRP in serum was measured by immunoturbidimetric method. Results： The level of MMP-9 in CHD with T2DM （M=409.62 ng/mL） was significantly higher than that of CHD group （M=263.40 ng/mL）（P〈0.05）and the control group（196.15±44.89）ng/mL（]P〈0.05）. The level of TIMP-1 in CHD with T2DM （229.27±46.85）ng/mL] was significantly lower than that of control group （272.75±72.35）ng/mL（]P〈0.05）. The level of hs-CRP in CHD with T2DM（M=17.20 mg/L） was significantly higher than that of CHD group （M=4.57 mg/L（）P 〈0.01）and that of the control group（1.52±0.78）mg/ L（]P〈0.01）. MMP-9 and TIMP-1 were significantly related with hs-CRP in CHD with T2DM （r =0.482, P〈0.01）（r =0.458,P〈0.05）]. Conclusion： Combined detection of serum MMP-9,TIMP-1 and hs-CRP can be used as effective clinical parameters forecasting diabetes related coronary atherosclerosis.